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Quality-by-design in pharmaceutical development: 
From current perspectives to practical applications
Current pharmaceutical research directions tend to fol-
low a systematic approach in the field of applied research 
and development. The concept of quality-by-design 
(QbD) has been the focus of the current progress of phar-
maceutical sciences. It is based on, but not limited, to risk 
assessment, design of experiments and other computa-
tional methods and process analytical technology. These 
tools offer a well-organized methodology, both to identify 
and analyse the hazards that should be handled as criti-
cal, and are therefore applicable in the control strategy. 
Once implemented, the QbD approach will augment the 
comprehension of experts concerning the developed ana-
lytical technique or manufacturing process. The main 
activities are oriented towards the identification of the 
quality target product profiles, along with the critical 
quality attributes, the risk management of these and their 
analysis through in silico aided methods. This review 
aims to offer an overview of the current standpoints and 
general applications of QbD methods in pharmaceutical 
development.
Keywords: quality-by-design, pharmaceutical develop-
ment, risk assessment, software-aided development
INTRODUCTION
The traditional approach for assuring and maintaining product quality was an empi-
rical method based on trial and error, which grounded on a ceteris paribus concept known 
as the OFAT-method (one-factor-at-a-time). This approach carried the risk to incorporate 
the possibility of the occurrence of unexpected, out-of-specification results not only during 
process optimization, but also at the validation stage, which derived from insufficient 
product and process understanding. Although process validation is the golden standard 
in pharmaceutical development, presently in order to assure product quality and to gain 
background knowledge and thorough process understanding, the International Conference 
on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human 
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ICH Q8 guideline, QbD is defined as a systematic approach to product development; more 
precisely, it centres on designing manufacturing processes and product formulations from 
the earliest possible stage of development. Implementing QbD in the research and develop-
ment of pharmaceutical products requires a predefined objective and a deeper under-
standing of formulation and manufacturing process variables. Identifying the causes of 
quality issues through the understanding of the aforementioned variables ensures the 
implementation of a control strategy, and the development of a pharmaceutical product 
with pre- and well-defined quality standards which aims to match patients’ desideratum, 
and thus assuring the proper compliance.
The aim of this work is to summarize the current viewpoints regarding the position 
of QbD in pharmaceutical development and its application in both analytical and techno-
logical (manufacturing) context. Thus, this work represents a useful starting point for 
specialists in the pharmaceutical industry to become familiarized with QbD terminology, 
offering examples for the use of these methods in various contexts, as well as indicating 
other comprehensive reviews that expound specific aspects of this concept.
CURRENT REGULATORY DEMANDS AND TRENDS IN PHARMACEUTICAL 
DEVELOPMENT REGARDING QUALITY-BY-DESIGN
Requirements for product quality are described in the tripartite guidelines of ICH, i.e., 
Q8 (pharmaceutical development), Q9 (quality risk assessment) and Q10 (pharmaceutical 
quality system). The ICH Q8 guideline establishes the elements of pharmaceutical develop-
ment, namely, the quality target product profile (QTPP), critical quality attributes (CQAs), 
critical process parameters (CPPs), risk assessment (RA), design space, control strategy and 
product life-cycle management. The ICH Q9 guideline discusses the general principles 
of risk management and the use of risk analysis tools, whereas the ICH Q10 guideline 
provides guidance for science- and risk-based regulatory approaches, in addition to quality 
management (3–5).
In the past decade, further guidelines have been elaborated by ICH, aiming to com-
plement or clarify different concepts, strategies or regulatory demands already imple-
mented in previously published guides (ICH Q8-Q10). In this view, ICH Q11 supplements 
the information mainly, but not exclusively, described in the tripartite guideline of ICH Q8, 
Q9 and Q10, concerning the identification of quality target product profiles (QTPPs) and 
critical quality attributes (CQAs), development of experimental design space and appro-
priate control strategies for quality assurance throughout product life-cycle (6). In addi-
tion, the implemented ICH Q12 extends the use of QbD in pharmaceutical life-cycle manage-
ment in the commercial phase, in terms of post-approval change management in CMCs 
(chemistry, manufacturing and controls) (7).
QTPP is the summary of the product’s quality characteristics in regard to safety and 
efficacy, taking into account the route of administration, dosage form, delivery system, 
dosage strength, drug quality criteria (sterility, purity and stability) and others.
CQAs are physical, chemical, biological, or microbiological properties associated with 
the drug substance, excipients, intermediates or drug product that should be within an 
appropriate limit, range or distribution. The identification of the product and intermediate 
CQAs is followed by the determination of material attributes and process parameters that 
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may affect CQAs. Process parameter variables influencing CQAs are defined as critical 
process parameters (CPPs) that should be monitored or controlled to ensure quality. Criti cal 
material attributes (CMAs) are not defined by the ICH guidelines; however, they are still 
used as physical, chemical, biological, or microbiological properties of the input materials 
that should be within an appropriate limit.
Process analytical technology (PAT) is a system for monitoring the aforementioned 
attributes (CQA, CMA and CPP) while increasing the efficiency of detecting failures com-
pared to end-product testing, therefore minimizing the volume of rejected products (8).
Recently two concept papers have been elaborated by the ICH, namely, ICH Q13 
 focusing on continuous manufacturing and ICH Q14 dealing with the analytical QbD 
approach. ICH Q14 comes into the revision of the ICH Q2 guideline and aims to compen-
sate for the lack of analytical development viewpoints in the ICH terminology, and to 
cover new and innovative areas of analytical method development (e.g., near-infrared or 
Raman spectroscopy) (9, 10). The connection between the attributes presented above, 
namely, relationships between input CMA, CPP, output CQA and system monitoring PAT 
are given in Scheme 1.
Despite QbD not yet being mandatory for product development and manufacturing, 
this approach and/or some of its elements have been adopted in the pharmaceutical indus-
try, with RA being one the most frequently used tool next to experimental designs (11). In 
a systematic review presented by Grangeia et al. (12) RA as a QbD tool was performed in 
almost 50 % of cases, whereas screening, or optimizing the design of experiments (DoEs) 
were conducted in almost 75 % according to the presented literature survey, making the 
latter one the most frequently used QbD tool in pharmaceutical development. In a timeline 
of QbD implementation RA, followed by DoE, assisted or not by other in silico techniques 
(e.g., multivariate data analysis), generally contributes to the definition of a design space 
where operable control strategies (e.g., PAT tools) can be implemented in order to assure 
product performance.
RISK ASSESSMENT METHODS FOR CONTROL STRATEGY OF PHARMACEUTICAL 
PROCESSES
As mentioned before, quality by design based on RA is widely used in pharmaceutical 
R&D. In the past decades, various RA methods have been proposed in order to evaluate, 
identify and eventually control hazards that might have a critical impact on general pro-
cesses and/or product quality. The ICH Q9 guideline stipulates a typical process for risk 
Scheme 1
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management, generally including five important steps during the implementation of a RA, 
as follows (4):
(i) risk initiation – in this step the definition of the potential hazard on the process is 
formed and an established core team will set up a timeline, in order to evaluate, control 
and communicate the outcome of the risk management process;
(ii) RA – including the identification, analysis and evaluation of risks, using different 
RA methods (preliminary hazard analysis – PHA, fishbone/Ishikawa chart, failure mode 
and effects analysis – FMEA, failure mode and effects critical analysis – FMECA, fault tree 
analysis – FTA, hazard analysis and critical control points – HACCP, risk ranking and fil-
tering matrices);
(iii) risk control – comprising of risk reduction, generally through several preventive 
measurements, or risk acceptance, when hazard mitigation through the implemented 
 actions is not satisfactory;
(iv) risk communication – disclosure of the outputs obtained after risk analysis and 
control;
(v) risk review – this step represents the re-evaluation of the risk management, as new 
and much vaster knowledge and experience are obtained about the process.
Amongst the various RA methods, PHA, fishbone charts, FMECA and FTA are the 
most widely used in pharmaceutical development-related hazard control.
Preliminary hazard analysis (PHA). – The PHA is a qualitative RA tool, which is often 
used to initiate the risk analysis. Its main advantage lies in the rapid overview of the major 
risks in the early lifecycle of the development, although in a non-systematic way. Risk 
evaluation through PHA requires general brainstorming techniques, as it is based on the 
previous experiences of the team members (13, 14). Therefore, PHA is not sufficient when 
solely used, it must be followed by comprehensive analysis, e.g., hazard and operability 
study (HAZOP), or FMECA (15). The tool offers a tabular overview, containing, but not 
limited to, information about the hazard itself, a list of identified accidents, accident risk 
classification, description of system functions and human error contribution to accidents 
leading to hazardous events (15).
Cause and effect diagram. – Cause and effect diagram (Ishikawa diagram, fishbone 
chart) was developed by Karou Ishikawa in the late 1960s, being one of the most frequently 
used RA techniques nowadays. The chart is composed of two major parts. The “head of 
the fish” represents the CQAs, which have to be controlled, whilst the “body with ribs” 
contains the underlying causes that, left uncontrolled, might lead to the defined failure 
(16). The main branches, or primary causes, are commonly based on six basic categories, 
known as the six Ms (materials, man, machine, milieu, measurements and method) (17). 
The technique offers a general but systematic overview of the potential hazards (Fig. 1) and 
it is frequently associated with other RA techniques, oftentimes FMECA.
Failure mode and effects critical analysis (FMECA). – FMECA is one of the most important 
RA tools, used to identify the hazards and threats that can affect the defined aims and 
objectives of a process (18). The method uses the analysis and categorization of the poten-
tial risks based on their severity, occurrence and detectability on an arbitrary scale defined 
by the working group employed in the evaluation tasks. Afterwards, a risk prioritizing 
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number is calculated as a product of the three characteristics of the hazard. Preventive and 
corrective measurements will be formulated and implemented only for those process para-
meters that are considered as candidates for carrying a risk. In this view, FMECA is a 
valuable tool for risk management and is recommended as a complementary activity for 
method validation in both analytical (19, 20) and technological processes (21).
Fault tree analysis (FTA). – FTA, in contrast to FMECA, is a top-down RA method, 
which seeks to uncover the root cause of a risk. FTA is frequently combined with FMECA 
in the risk management approach to analyse hazards (22). This diagrammatic analysis 
applies Boolean logic gates (e.g., and, or, inhibit) and transfer symbols in order to establish 
relationships between lower-level events, such as basic, conditioning, intermediate and 
external events (23).
Application of RA in pharmaceutical development. – Among the existing RA methods 
Ishikawa chart and FMECA analysis are the most preferred methods in pharmaceutical 
development and are generally used in connection with each other (12). In the current 
 research trends, RA has been extensively used in both pharmaceutical manufacturing and 
analytical method development.
A pertinent example for RA-based development as an integrated part of the QbD was 
elaborated by Iurian et al. (24) for a prolonged release delivery system containing paliperi-
done as active substance. Controllable CQAs (mass uniformity, crushing strength and in 
Fig. 1. A general sketch representing hazard analysis applying the Ishikawa diagram. A putative or 
empirically observed defect might have several primary causes, which can be systematically analy-
sed. Conclusively, the root causes can be identified and the working group can implement proper 
control strategies.
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vitro release kinetics) for product performance were defined using a fishbone diagram 
based on the defined QTPPs established by preliminary studies. The CPPs underlying the 
identified CQAs were further analysed by FMEA. In a work presented by Mishra et al. (25) 
RA based on Ishikawa diagram and PHA was used in order to elucidate factors that influ-
ence the defined QTPPs in the case of carbamazepine containing orally disintegrating 
tablets. Zhang et al. (26) applied the Ishikawa diagram as an appropriate quality RA tool 
for the identification of CQAs in the case of a stability-indicating RP-HPLC method for a 
forced degradation study of cloxacillin. In their study, five factors (pH of the buffer solu-
tion, solvent type, solvent content, concentration of the buffering salt and column temper-
ature) have been identified, which were afterwards screened for their significant effect 
using experimental designs. After an initial screening, with the help of Pareto charts, the 
factors were ranked based on their significance on method performance and were further 
optimized with the help of DoE, whilst the other two statistically insignificant factors were 
kept constant further on. An interesting approach to analyse and investigate hazards in 
the case of HPLC method development was presented by Reid et al. (27). The technique 
successfully applied both an Excel-based analysis and a software-aided approach in order 
to identify and categorize risks that influence a chromatographic system.
The outcome of risk analysis is generally the definition of the CQAs, which need to be 
analysed and controlled in order to gain in-depth knowledge and to assure proper robust-
ness of the developed methods and manufacturing processes. For this purpose, soft-
ware-assisted tools have obtained increased attention and have been extensively used. 
Proper risk analysis of influencing factors underlying CQAs, generally performed by a 
multidisciplinary team, is the fundamental prerequisite for the establishment of a subse-
quent DoE screening and optimization required in both analytical and technological 
fields.
QUALITY-BY-DESIGN IN THE DEVELOPMENT OF ANALYTICAL METHODS 
AND PHARMACEUTICAL MANUFACTURING
Method development strategy – a general workflow of AQbD implementation. – The concept 
of QbD, widely used in the pharmaceutical industry, can be applied in development of 
analytical methods and validation, known as analytical quality by design (AQbD). It was 
introduced by the US Food and Drug Administration and reported in the ICH Q8(R2) 
guideline (3, 19), although these documents elaborated by major regulatory bodies have 
been preceded by pioneering studies in this field of research (28). There are many analyti-
cal methods developed using the AQbD approach, such as enantioseparation and purity 
determination by capillary zone electrophoresis (29, 30), Karl Fischer titration for determi-
nation of water content (31), spectroscopy for quantitative colour measurement (32), etc. 
Analytical methods that are commonly used for quality control (assay, stability, content 
uniformity and impurity profile) are mainly based on chromatographic techniques (HPLC, 
UHPLC, LC-MS, SFC, GC), thus considering the empirical relevance of these methods, in 
this section we propose to review the relevant information regarding the application of 
AQbD in chromatographic methods.
(i) Definition of the analytical target profiles (ATPs). – The key component and the first step 
of the AQbD is to determine the analytical target profile (ATP) (33), the aim of the devel-
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oped analytical method (34) without identifying the method development steps and the 
method itself. An up-to-date definition of ATP was formulated by Jackson et al. (35) stipu-
lating that “ATP, in a similar fashion to the quality target product profile (QTPP), prospec-
tively summarizes the requirements associated with a measurement on a quality attribute 
which needs to be met by an analytical procedure and is used to define and assess the 
fitness of an analytical procedure in the development phase and during all changes across 
the analytical lifecycle”.
For an adequate ATP definition, it is important to know the matrix, the physicochemical 
properties of the main analyte/analytes (pKa, solubility and stability), and so on. For  example, 
in the case of azilsartan, medoxomil and chlorthalidone hydrochloride containing tablets 
the ATP is the determination of these active ingredients in the presence of their degrada-
tion products, providing suitable specificity due to structural similarities (36).
Along with the specification of the scope of the method (e.g., naming the main ana-
lyte), the ATP can include the definition of some performance criteria of the method, per-
formance characteristics of CMAs and operational factors (analysis time, specificity, rela-
tive retention time, linearity range, etc.) (33, 37, 38). The ATP should be valid not only across 
the method development and validation phase but also during the method transfer, there-
fore, precision and accuracy of the method are frequently included as ATP criteria (39).
(ii) Definition of CMAs and CMPs and performing RA. – Critical method parameters, 
CMPs [termed as critical process parameters (CPP) in QbD] are defined as variables that 
affect the resulting method, which are evaluated by the critical method attributes (CMAs) 
[used as critical quality attributes (CQA) in QbD].
In the case of an HPLC/UHPLC method, these CMAs can be peak symmetry, tailing 
factor, peak width, analysis time, the resolution between two peaks, theoretical plates, 
signal-to-noise ratio, etc. (40–43). In the case of a complex matrix (e.g., plant extract, bio-
logical matrix) the definition of CMA can be difficult (if in any condition the CMA varies 
between the preferred intervals, it cannot be considered a CMA) (44).
The CMPs are determined based on preliminary experiments and literature data. The 
most common parameters, which serve as CMPs, are column temperature, mobile phase 
flow rate, organic modifier (acetonitrile, methanol) percentage, gradient time, injection 
volume, mobile phase pH. If an MS detector is used, there are other CMAs influencing 
parameters (spray voltage, sheath gas and auxiliary gas pressure) in addition to the above-
mentioned ones. The CMPs of GC methods can be the oven temperature and program, and 
carrier gas velocity (44–46).
Risk factor identification through prior knowledge, risk analysis through Ishikawa 
diagram, along with risk evaluation through FMECA, identify and prioritize the main 
factors that could influence CMAs and consequently the ATP. Risk factors can be classified 
as high-risk factors, which should be eliminated during the method development process, 
noise factors, which are recommended to be tested by robustness studies, and experimen-
tal factors, required to be studied by ruggedness test (33, 47). Most frequently, Ishikawa 
diagrams are used to help in the identification of risk factors in AQbD including the 
 following: environment, materials, method, human factor, and machine (39).
(iii) Use of experimental designs (DoE) for method development. – DoE is a systematic 
 approach to determine the relationship between input and output variables through 
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 mathematical models. The number of experiments can be reduced by systematically and 
purposefully varying experimental parameters to maximize the available information 
and identify the effects of process and product parameters on response variables. In addi-
tion, DoE is used to determine CPPs, their interactions, and identify the optimum settings 
of these parameters in order to maintain CQAs (48, 49). The NIST (National Institute of 
Standards and Technology) handbook identifies the following steps in the process of a DoE 
(50):
– determination of the objectives, which implies identifying the QTPP;
– selection of process variables, both inputs and outputs (CPPs, CQAs);
– selection of experimental design;
– execution of the experiment;
– verification of data consistency with experimental assumptions;
– analysis and evaluation of results;
– interpretation and use of the results.
There are many DoE tools, assisted by several software programs, mainly based on 
linear solvent strength theory (51). The most frequently used methods in practice are listed 
in Table I. The screening designs are applied for the selection of CMPs and CMAs and are 
followed by DoE experiments used for method optimization. Application of DoE is part of 
the AQbD approach, but not the only step; however, there are papers where the two terms 
are misinterpreted.
A recent study presented by Sylvester et al. (52) follows a step-by-step AQbD develop-
ment and validation of an HPLC method for the separation of curcumins and doxorubicin 
from a long-circulating liposome formulation using a D-optimal experimental design. 
 Using a gradient HPLC method the critical step in method development and thus in DoE 
was the optimization of the gradient elution program defining the time span for the two 
solvents at a given percentage, in the initial isocratic hold and purging time. In addition to 
the duration of the linear-gradient, the initial and final percentage of the two components 
of the mobile phase could also represent CMPs (44). In all cases, DoE experiments are for 
HPLC method fine-tuning, previously reported methods or preliminary experiments 
 being the starting point. Numerous reverse phase HPLC methods optimized using AQbD 
are published, but there are several using gradient HILIC (hydrophilic interaction 
chromato graphy) methods as well (53). Using isocratic HPLC methods, the most frequent 
CMPs are the aforementioned input variables (54, 55).
In a recent study published by Saha et al. (42) a simple, rapid and robust UPLC-MS 
method was developed for atazanavir sulphate using the AQbD approach. Implementing 
a combined technique of Ishikawa followed by FMEA risk analysis, factors (percent of 
organic modifier, flow rate and injection volume) that critically affect selected responses 
(analyte retention time, theoretical plate number, peak tailing and column) have been 
identified. The four factors were initially screened using a fractional factorial design for 
their influence on CQAs. As column temperature lacked a significant impact on method 
performance this was kept constant in the further stages of the method development and 
the remaining three factors were optimized using a Box-Behnken experimental design. 
After defining the method operable design region (MODR) using the 3D surface plots, 
method validation was carried out, with the exception of robustness testing, which in the 
case of experimental design is often embedded in the MODR.
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Another study, presented by Kumar et al. (56) described the development and valida-
tion of an HPLC method for the determination of valsartan in nanoparticles. DoE table was 
set up based on a full factorial design, including flow rate, detection wavelength and pH 
of the buffer solution as factors, noting the peak area, tailing factor and theoretical plate 
number as responses. The optimized parameter settings performed well in terms of pre-
dicted vs. observed response values, indicating a well-established MODR using DoE assis-
tance. Further method validation was carried out with the optimized settings as per the 
requirements of the ICH guidelines. Once again, robustness testing was considered to be 
an integrated part of the defined MODR.
Similarly, we previously developed an RP-HPLC method for the quantification of fam-
pridine from the solid oral dosage form by applying a full factorial experimental design 
(55). A MODR was achieved in terms of flow rate, column temperature and buffer propor-
tion in the mobile phase, for chromatographic system CQAs (retention time, theoretical 
plate number and tailing factor). In addition, during the validation phase, method robust-
ness was tested using a Plackett-Burman experimental design, in order to show that small 
modifications in parameter settings do not influence in a significant way the selected 
 responses. This observation is based on markedly lower goodness of fit and goodness of 
predictability values when compared to those obtained during the screening type exper-
imental design. Robustness testing through a Plackett-Burman model was also carried out 
by Maškovic et al. (57) for perindopril tert-butylamine in the presence of its related impu-
rities. Through DoE the non-significant intervals for seven factors (column type, acetoni-
trile content, temperature, mobile phase pH, potassium dihydrogen phosphate concentra-
tion, flow rate and wavelength) were obtained; furthermore, system-suitability tests were 
performed and adjacent acceptance range was defined in certain cases.
Analysing the most frequently defined CMAs, these depend on the determined ATP: 
the resolution of two peaks, if impurities are measured beside an active pharmaceutical 
ingredient or structurally similar compounds (40, 53, 54, 58), analytical sensitivity and 
analysis time if the analytes are measured in a complex matrix (44).
Selecting the suitable DoE tool depends on the aim of the study (screening or optimi-
zation), the number of variables and the knowledge on the impact the input variables have 
on results (if it is available).
(iv) Definition of a method operable design region (MODR). – Another important step in 
method development is defining MODR, also known as analytical design space. Design 
space is defined as the “multidimensional combination and interaction of input variables 
that have been demonstrated to provide assurance of quality” (3). MODR is the region of 
robustness, where the effect of CMPs (input variables) on CMAs meets the desired ana-
lytical parameters drafted by ATPs (59). Determination of MODR during the method de-
velopment phase can substitute the robustness testing at the end of the method validation 
(42). The importance of the design space is highlighted when transferring methods 
 between laboratories; additional validation steps are required only if the condition is 
moved out of the design space. For this purpose, two complementary design spaces should 
be determined: column design space and eluent (and other variables) design space (60), but 
in many cases only the second one is tested.
Various DoE techniques (Box-Behnken design, fractional factorial design, etc.) can be 
used for robustness testing, small changes in CMPs (flow rate, organic modifier percentage, 
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column temperature, wavelength, etc.) are tested, to evaluate if they have significant effects 
on CMAs (40, 61).
In order to better visualize the effects of the input variables (such as pH, temperature, 
flow rate, etc.) on CMAs, response surface analysis (2D or 3D response surface plot) can be 
applied, which shows the complex, non-linear interactions between the studied factors on 
quality performances (42, 61). A general workflow presenting the steps of AQbD is illu-
strated in Scheme 2 (28, 62, 63).
Proper analytical method development assisted by computational tools is of utmost 
importance in modern pharmaceutical research and development as it contributes to the 
endowment of proper manufacturing technology and simultaneously represents the 
 mirror of compositional or technological modifications encountered during formulation 
optimization.
Quality-by-design in pharmaceutical manufacturing. – Over the past decade, the pharma-
ceutical manufacturing processes have started to be based extensively on the principles of 
quality-by-design, as the standards of international authorities have greatly risen. Today, 
both RA and DoE are widely used to assure product quality and process ruggedness dur-
ing the manufacturing of solid and liquid pharmaceutical dosage forms.
The main steps to be considered during pharmaceutical QbD are quasi-similar to 
those described in the previous section. First, the definition of QTPPs has to be performed, 
which might be based on empirical considerations, or in the case of generic product develop-
ment, on the physical and in-process control characterization of the original product. In 
this context, QTPPs will establish the definition of the CQAs, which need to be controlled 
Scheme 2
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by implementing a well-established control strategy based on RA and experimental  design, 
while taking into consideration the CMAs and CPPs of the pharmaceutical formulation 
and manufacturing technology, resp. (8, 64).
The QbD strategy has been successfully applied in the optimization and comprehen-
sion of different pharmaceutical technological processes. The CPPs in pharmaceutical 
manufacturing have multifactorial and process-related particularities. Solid oral dosage 
forms (e.g., tablets, capsules) are the most preferred forms of patient medication. The clas-
sical manufacturing processes imply dry blending or granulation techniques either via 
wet- (fluid bed granulation or high-shear mixing and granulation), or dry-routes (roller 
compaction) (65).
In the case of dry blending, formulation excipients, such as fillers, lubricants and dis-
integrants have an important impact on manufacturability and product quality. For a 
proper die filling during tablet compression, it is of utmost importance to obtain good 
powder flow properties. This can be achieved by selecting larger particle size excipients, 
but keeping insight that the excipients’ distribution of particles is in the range of the APIs, 
in order to avoid material segregation and uneven dosage uniformity. During direct com-
pression, the compression force, or turret and feeder rotation speed ratios should be con-
sidered as CPPs. Compression force, as one should expect, would define tablet hardness 
and API dissolution from the tablets’ matrix, whereas the optimum turret and feeder rota-
tion speed ratio define the mass uniformity. Szabo et al. (66) investigated the effect of 
 formulation variables on the manufacturability of tablets containing a combination of 
enalapril maleate and indapamide. In their study, microcrystalline cellulose, croscarmel-
lose sodium and magnesium stearate had a noticeable impact on manufacturability and 
in-process control of tablets, while compression force was noted as the most influential 
process parameter on product performance characteristics.
Generally, in wet-route manufacturing, the wet-granulation will have the greatest 
impact on product QTPPs, as granule density, size and moisture content will subsequent-
ly influence the compressibility behaviour of the final powder blend and, consequently, in 
vitro and in vivo release kinetics. A wet-granulation system has two main components: (i) 
the internal phase, usually comprising the active ingredient and bulking excipients and 
(ii) the granulation liquid, generally purified water or an aqueous solution of selected 
binder excipients (starch or derivatives thereof, gelatine, polyvinylpyrrolidone, etc.). Granu-
lation liquid quantity and spray rates are common variables that should be considered for 
both fluid bed and high-shear mixing and granulation. In particular, during fluid bed 
granulation, inlet airflow and temperature, through moisture regulation and atomizing 
air pressures, through droplet size, will influence granule growth and compactness. In 
terms of high-shear mixing and granulation, impeller and chopper velocities are general-
ly considered as CPPs. In a study performed by Rambali et al. (67) inlet airflow, inlet air 
temperature, spray rate, inlet air humidity and powder bed moisture content were selected 
as process variables and powder rheology characteristics were noted as responses. Simi-
larly, Djuris et al. (68) have identified the binder addition rate, airflow and inlet air temper-
ature as CPPs. In such systems, the droplet size will affect granule growth and density, and 
usually spray rate will be the main influencing process parameter. Nevertheless, a con-
stant and controlled granule growth is the main goal, and in order to achieve this, all 
previously enumerated parameters should be carefully monitored throughout the develop-
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ment. This evolution is characterized by moisture content, which could be effectively mon-
itored in-line, by proper PAT devices, e.g., NIR spectroscopy.
Besides solid oral dosage form development and optimization, DoE is vastly used in 
several other pharmaceutical formulation techniques, such as hot melt granulation (69, 70), 
liquid dosage forms (71, 72), liposome formulations (73, 74) and nanostructured lipid car-
riers (75).
As quality demands and challenges arise in the pharmaceutical industry, several 
complementary software-aided tools gain more and more attention in order to assure 
product performance, among which artificial neural networks and multivariate data 
 analysis occupy a prominent place.
APPLICATION OF ARTIFICIAL NEURAL NETWORKS AND MULTIVARIATE DATA ANALYSIS 
AS COMPLEMENTARY TOOLS IN PHARMACEUTICAL DEVELOPMENT
Artificial neural networks. – An artificial neural network (ANN) is a computational 
model, which mimics the learning and generalization capabilities of the human brain by 
processing diverse input data and utilizing previous information or training to produce 
relevant output. ANNs are able to model complex non-linear systems, in which the con-
nections between variable parameters are unknown (76, 77). ANNs consist of processing 
units, which form three interconnected layers (input, hidden, output), so the output of one 
serves as input for the next. The input layer is formed by processing units that take up the 
information; the hidden layer is responsible for the processing and analysis of the input, 
which is then transferred to the output layer (Fig. 2). Supervised or unsupervised training 
can be used after structuring the network with randomly chosen weights. During super-
vised training, actual and anticipated outputs are provided, then compared to calculate 
errors, causing the system to adjust weights and reduce the value of error (78, 79). Training 
Fig. 2. Artificial neural network model. The processing units of each layer are interconnected. The 
input layer receives the input signals, which are passed to the hidden layer and finally to the output 
layer through weighted connections.
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is followed by a validation test using independent validation data, set in order to determine 
the capability of the model to predict correct output from unknown input data (80).
Deep neural networks (DNN) are feed-forward neural networks (FFNN) with multiple 
hidden layers in which information only travels forward. While shallow neural networks 
with a single hidden layer are faster to train and can run on machines with smaller resources, 
DNNs are able to model mapping with higher complexity and can be as effective as shallow 
neural networks when their parameters are optimized (81–83). In contrast to FFNNs, recur-
rent neural networks (RNN) have feedback loops, which allow signals to travel backward to 
previous parts of the network (84, 85). As a result, it allows information to persist and has 
the built-in capability of modelling sequential data, therefore, it is applied in model predictive 
control (MPC) (86, 87).
Pharmaceutical applications of ANNs include drug design, optimizing preformulation 
and formulation of various dosage forms, modelling in vitro-in vivo correlations, interpreting 
analytical data, determining the relationship between the chemical structure and biological 
activity of a substance (quantitative structure-activity relationship) as well as pharmaco-
toxicological, pharmacokinetic and pharmacodynamic studies (76, 88). ANN has been ad-
opted to predict the release rate from lignin-containing aspirin tablets (89) and the charac-
teristics of buccoadhesive pharmaceutical wafers containing loratadine (90). ANN models 
have been used to predict the disintegration time, friability and tablet hardness of orally 
disintegrating ondansetron tablets (91). Han et al. (92) compared the accuracy of the disinte-
gration time of orally disintegrating tablet formulations predicted with ANN and DNN 
techniques; DNN proved to be significantly better at providing real unknown data when 
compared to ANN. Ilić et al. (93) developed in vitro-in vivo correlation models based on ANN 
analysis in the case of nifedipine osmotic release tablets.
Furthermore, ANNs have been successfully used for in vitro release kinetics prediction 
of active substances from hydrophilic matrix formulations (94, 95). Moreover, in the past 
years, ANNs were combined with various computational tools, e.g., gene algorithms, for the 
evaluation of the pharmacokinetic parameters of alkaloid drugs (96). RNN has been applied 
in MPC of CQAs in continuous pharmaceutical manufacturing with favourable results (97).
Multivariate data analysis. – Multivariate data analysis (MVDA) is a statistical technique 
used to simultaneously analyse data sets with several variables often correlated with each 
other. The term chemometrics is often used when relevant chemical information is extracted 
from the experimental data. In addition to data analysis, the aim of MVDA is sample classi-
fication and prediction of response variables (98–100). This is achieved by a variety of multi-
variate methods, with principal component analysis (PCA) and partial least squares (PLS) 
being the most commonly used techniques for analysing continuous processes (101).
PCA reduces the number of variables in a process while retaining as much variability 
as possible. Correlated original variables are represented by principal components (PC) that 
explain the main variance in the data and are uncorrelated with each other. The first PC is 
the linear combination of the original variables, which accounts for maximum variability in 
the data. The second and subsequent PC capture as much of the remaining variability as 
possible. The resulting data set is easier to analyse, visualize and interpret (102, 103). PLS is 
also used to reduce the number of variables through linear transformations, however, these 
variables are calculated to maximize the covariance between different sets of variables 
 (independent or exogenous and dependent data sets) using the fewest dimensions. PLS is 
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especially useful in the case of small datasets, missing values and multicollinearity between 
predictors (68, 104). Both PCA and PLA are often combined with spectrophotometry in order 
to build simple, fast, efficient, low cost and non-destructive chemometric models that do not 
generate chemical waste.
PCA was implemented in order to examine the deformation of pharmaceutical powders 
during powder compaction (105) and to select the most important variables for developing 
a solid self-emulsifying drug delivery system for docetaxel (106). A combination of PCA and 
attenuated total reflectance Fourier-transform infrared spectroscopy (ATR-FTIR) was used 
to identify the polymorphic forms of mebendazole in tablets (107).
PLS was applied for the simultaneous quantitative determination of paracetamol and 
tramadol in paracetamol-tramadol tablets (108) and for the analysis of a binary mixture 
tablet containing bisoprolol fumarate and hydrochlorothiazide (109) from UV spectrophoto-
metric data. A method based on diffuse reflectance, middle infrared spectroscopy and PLS 
was used for simultaneous quantification of artesunate and mefloquine in tablets (110).
Both PCA and PLS have been useful in selecting suitable and desired CQAs of nano-
structured lipid carriers (111). Ali et al. (112) built a chemometric model by combining multi-
variate data analysis tools (PCA and PLS) and vibrational spectroscopy (FTIR/NIR) method 
for quantification of carbamazepine dihydrate in the formulation. Arabzadeh et al. (113) 
 developed a UV spectrophotometric analysis method based on ANN, PLS and principal 
component regression (PCR) for simultaneous determination of emtricitabine and tenofovir 
alafenamide fumarate in commercial HIV drug. Each method showed enough accuracy 
when compared to the reference method (HPLC), however, the ANN and the PLS method 
worked better than PCR. Combined use of PCA and ANN was developed for the multicom-
ponent determination of four drugs from a complex pharmaceutical mixture using UV spec-
troscopy, which gave the best results with a shorter convergence speed when compared to 
ANN (114).
Process analytical technology (and major process analyzers applied) in quality-by- 
- design. – Process analytical technology (PAT), is a relatively new concept to the pharmaceu-
tical industry, yet it has been already known previously as process analytical chemistry 
(PAC) in other industries. The FDA released the guidance on PAT in final form in September 
2004 as a framework for innovative pharmaceutical development, manufacturing and 
 quality assurance. The aim of the document was to enhance process understanding, leading 
to improved control of the manufacturing process. While the ultimate goal of QbD is to build 
quality into products by design, PAT plays a crucial role in its accomplishment. PAT tools 
and principles represent the means to achieve the aims of QbD. The application of PAT is 
encouraged by FDA representatives (115).
PAT is composed of multivariate (chemical, physical, microbiological and mathemati-
cal) methods for material and process analysis, containing also process modelling and 
enhanced control strategies in order to enhance product quality and process efficiency. 
PAT has involved concomitant with the decrease of measurement systems’ cost, develop-
ments in microsystem technology and the explosive increase of computational power ex-
perienced in the last decade (116).
Process analysers are the heart of PAT tools permitting real-time process monitoring 
and control. They generate the necessary data from which valuable information could be 
extracted about processes and products. Unlike conventional systems which provide uni-
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variate measurements, the PAT process analysers furnish multivariate information in con-
junction with biological, physical, and chemical attributes of the starting materials, inter-
mediates and finished drug products. The major considerations which should be taken 
into account when selecting process analysers into the technological flux are the following: 
the ability to properly monitor the process and/or product properties, defining measure-
ment conditions, proper location of the analyser and the validation of performance (117).
The vast majority of applications in the pharmaceutical industry rely on two of the 
vibrational spectroscopic techniques: near-infrared spectroscopy (NIR), followed by 
 Raman spectroscopy. These methods allow rapid and non-destructive measurements 
 providing versatile and multivariate information and have been implemented in the 
 common batch unit operations of the solid dosage form development and manufacturing 
processes for monitoring critical aspects. Besides the use of the NIR and Raman spectro-
meters in the application as in-line, at-line or on-line analyzers in many studies these are 
used as off-line tools. Further standard operations are imaging (for extracting morpho-
logical features) and mainly in the case of liquids UV-VIS analysis. However, other techno-
logies are quickly catching up and increasing the repository of possible PAT tools (116).
As published by Helešicová et al. (118) in the case of topochemical mapping of pharma-
ceutical tablets from microtome slices with Raman microscopy the experimental setup is 
of great importance and depending on the resolution required, the selection of proper 
measurement type plays also a crucial role. Among others, the study highlights the use of 
advanced multivariate chemometric methods (as PCA and SIMCA) and encourages the 
application of different evaluation approaches in order to improve the reliability of gath-
ered information.
In a study presented by Mitsutake et al. (119) the Raman mapping in association with 
three different chemometric methods [(PCA, multivariate curve resolution alternating 
least square (MCR-ALS) and independent component analysis (ICA)] was applied in the 
investigation of the spatial distribution of components in case of semi-solid pharmaceutical 
systems and predicting their stability and possible physical transformations (118).
In a recent study, Nomura et al. (120) demonstrated the utility of a non-contact low-
frequency Raman probe in the real-time monitorization of polymorph conversion in the 
course of high-shear wet granulation. Four model drugs (indomethacin, acetaminophen, 
theophylline and caffeine) were involved in the study and were subjected to aqueous wet 
granulation in the presence of broadly used pharmaceutical excipients. The study also 
extended to the practical detection limit of API content, monitoring the hydrate transition 
of crystalline drugs, dissociation monitoring of co-crystals as well as the feasibility study 
of monitoring of commercial formulations. The obtained results were confirmed by X-ray 
powder diffraction analysis.
In a recent study, Gavan et al. (121) monitored the moisture content of the fluidised-bed 
step by the means of micro-NIR PAT-U in order to improve the supervision and control 
over the process. It was demonstrated that NIR analysis is a reliable PAT tool and might 
substitute the currently broadly applied loss on drying measurement based on a gravimet-
ric method (119).
Casian et al. (122) validated and compared NIR and Raman spectroscopic methods for 
the characterization of fixed-dose combination tablets. They managed to establish highly 
predictive computational models for quantification of API by NIR-transmission and 
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 Raman-reflectance as well as NIR transmittance for tensile strength in case of amlodipine 
and valsartan-containing tablets.
Among the emerging techniques that started to be implemented in the PAT, terahertz 
(THz) spectroscopy should be mentioned which uses THz pulses generated and detected 
by short-pulsed lasers. The pulse widths are ranging from  ̴10–100 femtoseconds and are 
characteristic to terahertz spectroscopy in comparison to conventional far-IR investiga-
tions. As the majority of crystalline solids exhibit characteristic lattice vibrations in this 
specific spectral range, this technique could be applied in the investigation of inter-
molecular interactions of molecular crystals. These characteristics might be explored in 
polymorph screening, mapping of chemical compositions, determining tablet density and 
for characterizing the film-coatings among others (123, 124).
Another promising spectroscopic method which should be noticed in conjunction 
with PAT is nuclear magnetic resonance (NMR) spectroscopy. This method was already 
applied for the quality control and authenticity of pharmaceutical products and its impor-
tance will surely increase in the upcoming period (125). More and more techniques are 
emerging and trying to find their place in the PAT approach of product development and 
manufacturing, therefore, without being exhaustive, novel methods as optical coherence 
tomography (OCT), acoustic emission (AE), microwave resonance (MR), and laser-induced 
breakdown spectroscopy (LIBS) should also be mentioned (126). In view of particle size 
on-line measurement essential to the proper monitorization of the widely used granula-
tion process, the methods which have been developed and implemented as PAT tools are 
imaging, focused beam reflectance measurement (FBRM) and spatial filter velocimetry 
(SFV) (127). The last two rely on the so-called chord length distribution (CLD) approach 
which measures the length of the signal generated by the interaction between the laser 
beam and the particles analysed (126). These techniques have been successfully applied in 
the growth kinetics monitoring during the fluidized bed- (128, 129) and high-shear wet 
granulation processes (130).
In PAT the data collected from different locations and varying instruments have to be 
combined with conventional data processing into meaningful relationships. After data 
consolidation, this information can be used in feedback or even feed-forward control loops 
with different complexity. This is achieved without further testing procedures, realizing 
real-time release testing (RTRT). In practice this step is critical and tests are often substi-
tuted one-by-one. Via in-line, on-line or at-line measurements throughout the manufactur-
ing process stream with enough confidence in the data, and enough accuracy in the quanti-
tative predictions, the obtained information can be used to directly assess the quality of 
the products and might make attainable the real-time release (RTR) (116).
CONCLUSIONS
Assuring and controlling the quality and robustness of the methods for manufactur-
ing pharmaceutical dosage forms has involved important changes in the past decades. 
Several guidelines have been imposed to identify, evaluate and control potential hazards, 
which might lead to undesirable out-of-specification product results and eventually a 
greater batch-to-batch variation. In the current view, standalone RA, or RA augmented by 
various in silico methods are used for the aforementioned purposes. The implementation 
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and application of the computational methods for QbD represent one of the key future 
perspectives and challenges. Although at first sight the complex nature of QbD might seem 
to significantly increase costs and be more time-consuming when compared to the OFAT 
concept, the late-stage advantages during scale-up to pilot, or industrial scale is unques-
tionable, and represent an opportunistic approach for constant quality assurance through-
out the product lifecycle. In this perspective, complementary tools and techniques, like 
ANN, MVDA and PAT will further augment these novel orientations in pharmaceutical 
R&D, contributing to enhanced quality assurance in the pharmaceutical industry.
The intent of this article was to provide a general overview of possible applications for 
QbD in the pharmaceutical industry, including examples where these methods have 
 already been successfully used and identifying relevant publications containing a  detailed, 
mathematical approach for the presented concepts.
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Acronyms, abbreviations, symbols. – AE – acoustic emission, ANN – artificial neural networks, 
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CMA – critical material attributes (technologic aspects)/critical method attributes (analytical aspects), 
CMC – chemistry, manufacturing and controls, CMP – critical method parameters, CPP – critical 
process parameter, CQA – critical quality attributes, DNN – deep neural networks, DoE – design of 
experiments (experimental design), FBRM – focused beam reflectance measurement, FFNN – feed 
forward neural networks, FMEA – failure mode and effects analysis, FMECA – failure mode and 
 effects critical analysis, FTA – fault tree analysis, HACCP – hazard analysis and critical control points, 
HAZOP – hazard and operability study, ICA – independent component analysis, LIBS – laser induced 
breakdown spectroscopy, MCR-ALS – multivariate curve resolution alternating least square, MODR 
– method operable design region, MPC – model predictive control, MR – microwave resonance, 
MVDA – multivariate data analysis, OCT – optical coherence tomography, OFAT – one-factor-at-a-
time, PAC – process analytical chemistry, PAT – process analytical technology, PAT-U – type of 
 apparatus used for the determination of moisture (ref. 121), PC – principal components, PCA – principal 
component analysis, PCR – principal component regression, PHA – preliminary hazard analysis, PLS 
– partial least squares, QbD – quality-by-design, QTPP – quality target product profile, RA – risk 
 assessment, RNN – recurrent neural networks, RTR – real-time release, RTRT – real-time release 
 testing, SIMCA – soft independent modelling of class analogies, SFV – spatial filter velocimetry.
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